(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.21%) $0.928
(0.35%) $10.88
(0.04%) $0.793
(-0.33%) $92.27
Quarter results today
(bmo 2024-03-29)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology...
Stats | |
---|---|
Today's Volume | 112 228 |
Average Volume | 154 544 |
Market Cap | 27.24M |
EPS | €0 ( 2024-02-20 ) |
Next earnings date | ( €0 ) 2024-04-17 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.315 |
ATR14 | €0.00700 (2.41%) |
Volume Correlation
Biocartis Group NV Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Biocartis Group NV Correlation - Currency/Commodity
Biocartis Group NV Financials
Annual | 2022 |
Revenue: | €57.48M |
Gross Profit: | €27.68M (48.16 %) |
EPS: | €-1.080 |
Q2 | 2023 |
Revenue: | €29.49M |
Gross Profit: | €12.85M (43.58 %) |
EPS: | €-0.340 |
Q1 | 2023 |
Revenue: | €14.81M |
Gross Profit: | €-926 000 (-6.25 %) |
EPS: | €-0.170 |
Q4 | 2022 |
Revenue: | €31.12M |
Gross Profit: | €12.35M (39.67 %) |
EPS: | €-0.580 |
Financial Reports:
No articles found.
Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators